Navigation Links
Reprogramming the debate: stem-cell finding alters ethical controversy
Date:11/20/2007

MADISON - When University of Wisconsin-Madison researchers succeeded in reprogramming skin cells to behave like embryonic stem cells, they also began to redefine the political and ethical dynamics of the stem-cell debate, a leading bioethicist says. R. Alta Charo, a UW-Madison professor of law and bioethics, says the scientific finding could have far-reaching effects on the social dimensions of the ongoing controversy over embryonic stem cell research.

"This is a method for creating a stem cell line without ever having to work through, at any stage, an entity that is a viable embryo," Charo says. "Therefore, you manage to avoid many of those debates with the right-to life community."

The research alters the debates surrounding both human embryonic stem cell research and somatic cell nuclear transfer cloning. For ordinary embryonic stem cell research, it offers a means of obtaining pluripotent cell lines from a non-embryonic source. For cloning research, it offers a means to make customized, pluripotent cell lines without having to create an intermediate embryo that is a "clone" of an adult person, she says.

Charo says the discovery could remove objections from critics on both the right and left wings of the political spectrum.

To derive embryonic stem cells, it is necessary to remove critical cells from an embryo, resulting in its destruction. That triggers opposition from right-to-life critics of the research, who cite moral and ethical concerns. The research has also generated opposition from some members of the women's movement who object the use of stimulating drugs in women who agree to donate eggs for cloning research aimed at creating specialized embryonic stem cell lines.

The latest findings have the potential to render both of those objections moot, since the research showed that introducing four genes into cells derived from skin cells, called human fibroblasts, resulted in cells that essentially share all the features of embryonic stem cells - but without using or destroying embryos.

"It holds a great deal of promise for freeing this whole area of research from those two main sources of friction," Charo says. The discovery also creates questions about the future of government funding for traditional embryonic stem cell research, which in recent years has been a contentious political issue.

"It's going to fuel those who call for preferential federal funding only for non-embryonic stem cell research and it will certainly complicate any efforts to expand funding for embryonic stem cell research at the federal level," she says. Twice, Congress has passed legislation to overturn the Bush administration policy on embryonic stem cell research and allow funding for research using any embryonic stem cell lines, not just those designated by the administration in 2001. Twice, the president has vetoed it.

"Any piece of research like this that suggests that we can get cell lines that are equally usable without having to go through an embryo in intermediate steps is going to undermine any effort on the part of Congress to overturn the Bush policy," she says.

The latest discovery, however, is likely to suggest avenues of research that are already eligible for federal funding. Recently, the White House directed the National Institutes of Health to emphasize the funding of research that examines alternative means for obtaining pluripotent cell lines whose usefulness is comparable to that of human embryonic stem cells.

"No matter how well this new technique can be used for many of the disease-research and disease-treatment applications foreseen for embryonic stem cell and cloning research, however, calls for criminalization or wholesale de-funding of embryonic stem cell and cloning research are not warranted," Charo adds. "Criminalizing any area of science, as opposed to merely regulating it, would be contrary to the political and constitutional traditions of academic and scientific freedom, as well as the historical spirit of inquiry that characterizes this country."


'/>"/>

Contact: R. Alta Charo
racharo@wisc.edu
608-262-5015
University of Wisconsin-Madison
Source:Eurekalert

Related biology news :

1. Finding that 1-in-a-billion that could lead to disease
2. First finding of a metabolite in 1 sex only
3. Embryonic stem cell strategy advanced with UCSF finding
4. New prostate cancer research findings
5. NHGRI funds new Centers for Excellence in Ethical, Legal and Social Implications Research
6. Alternative food networks connect ethical producers and consumers and can lead to healthier eating
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... 2017  Aware, Inc. (NASDAQ: AWRE ), a ... results for its quarter and year ended December 31, 2016. ... was $3.9 million compared to $6.9 million in the same ... 2016 was $0.6 million compared to $2.6 million in the ... of 2016 was $0.5 million, or $0.02 per diluted share, ...
(Date:2/7/2017)... Ind. , Feb. 7, 2017 Zimmer ... leader in musculoskeletal healthcare, will present at the LEERINK ... New York Palace Hotel on Wednesday, February 15, 2017 ... live webcast of the presentation can be accessed at ... replay following the conference via Zimmer Biomet,s Investor Relations ...
(Date:2/2/2017)... Feb. 2, 2017   TapImmune, Inc. ... company specializing in the development of innovative peptide ... of cancer and metastatic disease, announced today it ... manufacturing of a second clinical lot of TPIV ... receptor alpha. The manufactured vaccine product will be ...
Breaking Biology News(10 mins):
(Date:2/22/2017)... ... February 22, 2017 , ... ProMIS Neurosciences (“ProMIS” or the ... diseases, today announced it has issued a scientific white paper entitled “Results from ... series of commentaries from ProMIS’s scientific team offering insight into the Company’s product ...
(Date:2/22/2017)... Origin (Origin Agritech, LLC, a subsidiary of Origin Agritech ... Arcadia (Arcadia Biosciences, Inc., NASDAQ: RKDA), a ... productivity traits and nutritional products, today announced their collaboration to achieve ... China to the United States ... ...
(Date:2/22/2017)... and SAN DIEGO , Feb. ... "Company") (OTCQB:CELZ) announced today expansion of its translational ... cell product through establishment of laboratory facilities in ... at the San Diego BioLabs facility, a biotechnology ... Novartis, and Sanofi. In November 2016, ...
(Date:2/21/2017)... ... February 21, 2017 , ... During HIMSS 2017, ... health applications, announced a partnership with Redox, a leader in cloud-based healthcare integration ... clinical systems while keeping data secure in the cloud. , The digital health ...
Breaking Biology Technology: